Abstract:The constant and the sudden emergence of zoonotic human and animal viruses is a significant threat to human health, the world economy, and the world food supply. This has necessitated the development of broad-spectrum therapeutic strategies to combat these emerging pathogens. Mechanisms that are essential for viral replication and propagation have been successfully targeted in the past to develop broad-spectrum therapeutics that can be readily repurposed to combat new zoonotic pathogens. Because of the importance of viral RNA capping enzymes to viral replication and pathogenesis, as well as their presence in both DNA and RNA viruses, these viral proteins have been a long-standing therapeutic target. Here, we use genome sequencing information and yeast-based platforms (YeRC0M) to identify, characterize, and target viral genome-encoded essential RNA capping enzymes from emerging strains of DNA viruses, i.e., Monkeypox virus and African Swine Fever Virus, which are a significant threat to human and domestic animal health. We first identified and biochemically characterized these viral RNA capping enzymes and their necessary protein domains. We observed significant differences in functional protein domains and organization for RNA capping enzymes from emerging DNA viruses in comparison to emerging RNA viruses. We also observed several differences in the biochemical properties of these viral RNA capping enzymes using our phenotypic yeast-based approaches (YeRC0M) as compared to the previous in vitro studies. Further, using directed evolution, we were able to identify inactivation and attenuation mutations in these essential viral RNA capping enzymes; these data could have implications on virus biocontainment as well as live attenuated vaccine development. We also developed methods that would facilitate high-throughput phenotypic screening to identify broad-spectrum inhibitors that selectively target viral RNA capping enzymes over host RNA capping enzymes. As demonstrated here, our approaches to identify, characterize, and target viral genome-encoded essential RNA capping enzymes are highly modular and can be readily adapted for targeting emerging viral pathogens as well as their variants that emerge in the future.

Exosome-mediated PROTAC delivery for treatment of RNA viral infections and zoonoses

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Harnessing PROTACs to combat H5N1 influenza: A new frontier in viral destruction

Antiviral PROTACs: Opportunity borne with challenge

PROteolysis Targeting Chimeras: A new cutting‐edge nanomedicine for colorectal cancer

Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics

Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease

mRNA PROTACs: engineering PROTACs for high-efficiency targeted protein degradation

Characterization, Directed Evolution, and Targeting of DNA Virus-Encoded RNA Capping Enzymes Using Phenotypic Yeast Platforms

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

Mrna PROTACs: Engineering PROTACs for High‐efficiency Targeted Protein Degradation

PROTACs technology for targeting non-oncoproteins: Advances and perspectives

PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Protein degradation: a novel computational approach to design protein degrader probes for main protease of SARS-CoV-2

PROTACs: Great Opportunities for Academia and Industry (an Update from 2020 to 2021).

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Developments of PROTACs technology in immune-related diseases